MNK - Mallinckrodt plc

NYSE - Nasdaq Real Time Price. Currency in USD
8.40
-0.02 (-0.24%)
At close: 4:02PM EDT

8.40 0.00 (0.00%)
After hours: 4:39PM EDT

Stock chart is not supported by your current browser
Previous Close8.42
Open8.56
Bid8.40 x 1100
Ask8.41 x 900
Day's Range8.35 - 9.05
52 Week Range8.28 - 36.65
Volume3,899,042
Avg. Volume2,861,539
Market Cap704.036M
Beta (3Y Monthly)2.91
PE Ratio (TTM)N/A
EPS (TTM)-41.21
Earnings DateAug 5, 2019 - Aug 9, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est17.69
Trade prices are not sourced from all markets
  • MarketWatch9 hours ago

    Drug maker stocks rally after AbbVie's deal to buy Allergan for 45% premium

    Shares of drug makers were getting a nice boost in premarket trading Tuesday, after AbbVie Inc.'s deal to buy Allergan PLC for a 45% premium. The SPDR S&P Pharmaceuticals ETF rallied 2.2% ahead of the open. Besides the 31% jump in Allergan's stock, among other shares seeing nice gains in the premarket, Mylan N.V. rose 2.7%, Endo International PLC climbed 4.5%, Theravance Biopharma Inc. hiked up 4.2%, Mallinckrodt PLC tacked on 2.7% and Perrigo Co. PLC gained 2.2%. Meanwhile, Medicines Co.'s stock shed 4.6%, after the company announced late Monday the public offering of $150 million worth of common stock. The pharmaceuticals ETF has lost 7.7% over the past three months through Monday, while the S&P 500 has gained 5.3%.

  • PR Newswireyesterday

    Mallinckrodt Achieves 50 Percent Enrollment for Phase 2B Trial Investigating the Use of Acthar® Gel (Repository Corticotropin Injection) in Amyotrophic Lateral Sclerosis (ALS)

    STAINES-UPON-THAMES, United Kingdom, June 24, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a leading global specialty biopharmaceutical company, today confirmed it has achieved 50 percent patient enrollment in the company's Phase 2B study designed to assess the efficacy and safety of Acthar® Gel (repository corticotropin injection) as an investigational treatment for amyotrophic lateral sclerosis (ALS). The U.S. Food and Drug Administration (FDA) previously granted the company's request for a Fast Track designation and orphan status for its Acthar Gel Investigational New Drug application in patients with ALS. Please see Important Safety Information for Acthar Gel below.

  • Barrons.comyesterday

    The U.S. Gets Hundreds of Millions From Big Pharma in Co-Pay Settlements

    The federal government has secured almost $850 million in settlements from the pharmaceutical industry since a Barron’s investigation revealed how companies used charities in ways that undermined efforts to hold back skyrocketing drug prices.

  • Mallinckrodt Presents Encouraging Data on Acthar Gel for RA
    Zacks11 days ago

    Mallinckrodt Presents Encouraging Data on Acthar Gel for RA

    Mallinckrodt (MNK) reports encouraging results from a phase IV study on Acthar for RA at the EULAR.

  • PR Newswire12 days ago

    All Primary and Secondary Outcome Targets Met in Mallinckrodt's Phase 4 Acthar® Gel (Repository Corticotropin Injection) Rheumatoid Arthritis (RA) Clinical Trial (n=259) with Data Presented at the European Congress of Rheumatology 2019 (EULAR)

    -- Study met primary outcome measure; 63 percent of patients with persistently active RA achieved low disease activity (LDA) as assessed by DAS28-ESR ¹ at Week 12 -- -- Randomized, placebo-controlled, ...

  • PR Newswire14 days ago

    Mallinckrodt to Present at BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference

    STAINES-UPON-THAMES, United Kingdom , June 11, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals  (NYSE: MNK), a global biopharmaceutical company, will present on Tuesday, June 25, 2019 , at the BMO Capital ...

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Mallinckrodt Plc.

    Mallinckrodt Plc NYSE:MNKView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is high * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NegativeShort interest is extremely high for MNK with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting MNK. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding MNK totaled $9.22 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Mallinckrodt Down After Agreement with DOJ for Litigation
    Zacks19 days ago

    Mallinckrodt Down After Agreement with DOJ for Litigation

    Mallinckrodt (MNK) expects to pay $15.4 million to DOJ in relation with the Questcor litigation.

  • Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?
    Zacks19 days ago

    Why Is Mallinckrodt (MNK) Down 47.4% Since Last Earnings Report?

    Mallinckrodt (MNK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzinga20 days ago

    Mallinckrodt Agrees To Pay $15.4M In DOJ Settlement Over Acthar Subsidies

    The Justice Department accused Questcor in the years 2010-2014 of using a patient charity as a means of improperly subsidizing Medicare copayments in order to continue raising prices of H.P. Acthar gel, according to Reuters.

  • MarketWatch20 days ago

    Mallinckrodt's stock falls after it expects to pay more than $15 million to resolve DOJ investigation

    Shares of Mallinckrodt PLC dropped 2.4% in afternoon trade Wednesday, after the biopharmaceutical company said it reached an agreement in principle with the U.D. Department of Justice to resolve the investigation into the legacy sales and marketing activities of Questcor, which Mallinckrodt acquired in August 2014. Mallinckrodt expects to pay $15.4 million in the settlement, which will not contain any admission of wrongdoing. Meanwhile, the company intends to "vigorously defend" itself against any wrongdoing, with respect to the DOJ's newly filed allegations that Questcor's charitable activities between 2010 and 2014 violated the False Claims Act and the Anti-Kickback Statute. The stock has tumbled 58% over the past three months, while the S&P 500 has gained 1.1%.

  • PR Newswire20 days ago

    Mallinckrodt Announces Agreement In Principle With U.S. Department Of Justice On Legacy Questcor Sales And Marketing Activities; Responds To Government Civil Litigation Involving Legacy Questcor Charitable Foundation Activities

    STAINES-UPON-THAMES, United Kingdom, June 5, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global specialty biopharmaceutical company, today reported the company has reached an agreement in principle with the U.S. Department of Justice (DOJ) to resolve the previously disclosed government investigation of Questcor's legacy sales and marketing activities, which is still subject to the finalization of certain terms. Under the civil False Claims Act settlement, Mallinckrodt expects to pay $15.4 million relating to legacy Questcor activities.

  • RM LAW Announces Investigation of Mallinckrodt plc
    PR Newswire25 days ago

    RM LAW Announces Investigation of Mallinckrodt plc

    BERWYN, Pa. , May 31, 2019 /PRNewswire/ --  RM LAW, P.C.  announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Mallinckrodt plc (" Mallinckrodt ...

  • Barrons.com25 days ago

    Mallinckrodt Stock is Falling Because the Wheels Might ‘Finally Come Off’

    PiperJaffray analyst David Amsellem downgraded the company from Overweight to Neutral, writing that developments last week had blown his bull thesis “to smithereens.”

  • PR Newswire25 days ago

    Mallinckrodt to Present at Raymond James Life Sciences and Medtech Conference

    STAINES-UPON-THAMES, United Kingdom , May 31, 2019 /PRNewswire/ --  Mallinckrodt Pharmaceuticals  (NYSE: MNK), a global biopharmaceutical company, will present on Wednesday, June 19, 2019 , at the Raymond ...

  • Cara Shares Up on Positive Phase III Data for Itchiness Drug
    Zacks26 days ago

    Cara Shares Up on Positive Phase III Data for Itchiness Drug

    Cara (CARA) reports positive top-line data from phase III study of Korsuva injection in hemodialysis patients with moderate-to-severe chronic kidney disease-related pruritus.

  • Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down
    Zacks27 days ago

    Mallinckrodt to Spin Off Specialty Generics Unit, Shares Down

    Mallinckrodt (MNK) will spin-off its Specialty Generics business to its shareholders.

  • PR Newswire27 days ago

    Mallinckrodt Announces Positive Open-Label Results from Phase 4 Acthar® Gel (Repository Corticotropin Injection) Clinical Trial in Rheumatoid Arthritis (RA) to be Presented at the European Congress of Rheumatology 2019 (EULAR)

    STAINES-UPON-THAMES, United Kingdom, May 29, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global specialty biopharmaceutical company, is reporting data1 from the open-label part of the Phase 4, multicenter study assessing the efficacy and safety of Acthar® Gel (repository corticotropin injection) in patients with persistently active rheumatoid arthritis (RA) who were previously treated with disease-modifying anti-rheumatic drugs (DMARDs) and corticosteroids. The data will be reported in a poster presentation on Thursday, June 13 at the European Congress of Rheumatology 2019 (EULAR), June 12-15 in Madrid.

  • Reuters28 days ago

    Mallinckrodt's Amitiza to stay with branded business after spin-off

    The company had said in December it was open to a sale of the generics business or would spin it off in the second half of 2019. It had said Amitiza would be part of the spun-off unit. Shares of Mallinckrodt were down 6.3% in noon trading, as concerns related to its Acthar gel continued to weigh on the stock.

  • TheStreet.com28 days ago

    Mallinckrodt Rises After Announcing Plans to Spin Off Specialty Generics Unit

    The stock was rising 5.49% in premarket trading, only to fall 1.77% to $9.44 in regular hours. Mallinckrodt will focus on specialty branded pharmaceuticals while Sonorant will focus on specialty generic products and APIs1 manufacturing. "I am very pleased with the highly experienced management team we have assembled," said Matthew Harbaugh, president of Mallinckrodt's specialty generics business.

  • Reuters28 days ago

    Mallinckrodt to spin-off generics business, keep constipation drug

    Mallinckrodt Plc said on Tuesday it would spin-off its specialty generics unit and rename the remaining specialty branded drugs business to Sonorant Therapeutics Plc. Sonorant will keep constipation medicine Amitiza, Mallinckrodt said. The company had said in December it was open to a sale of the generics business or would spin it off in second half of 2019.

  • PR Newswire28 days ago

    Mallinckrodt Updates Plans for Company Separation and Spin-Off of Specialty Generics Business to Shareholders

    STAINES-UPON-THAMES, United Kingdom, May 28, 2019 /PRNewswire/ -- Mallinckrodt plc (MNK), a global biopharmaceutical company, today announced updated plans for its spin-off of a new company consisting of Mallinckrodt's Specialty Generics/Active Pharmaceutical Ingredients (Specialty Generics) business to Mallinckrodt plc shareholders. The separation is intended to create two independent, appropriately capitalized, publicly traded companies – one focused on innovative specialty branded pharmaceuticals, the other concentrated primarily in specialty generic products and APIs1 manufacturing – with each positioned to optimize future success as they pursue independent growth strategies.

  • Cramer Remix: Why Chipotle's downgrade is misguided
    CNBClast month

    Cramer Remix: Why Chipotle's downgrade is misguided

    Jim Cramer explains why worries at the restaurant chain may be off-base.